One–year all–cause mortality in patients with CRC and T2D
(comparison between propensity–score matched semaglutide vs other anti–diabetic medications groups)

Size/Group	Exposure Group	Comparison Group	Exposure Group Cases (Overall Risk)	Comparison Group Cases(Overall Risk)	HR (95% CI)
553	semaglutide	anti–diabetics	15 (2.7%)	34 (6.1%)	0.42 (0.23–0.77)
505	semaglutide	other GLP–1RAs	14 (2.8%)	25 (5.0%)	0.55 (0.29–1.06)
561	semaglutide	insulin	15 (2.7%)	45 (8.0%)	0.31 (0.17–0.56)
547	semaglutide	metformin	15 (2.7%)	24 (4.4%)	0.60 (0.31–1.14)
481	semaglutide	DPP–4i	14 (2.9%)	18 (3.7%)	0.74 (0.37–1.49)
506	semaglutide	SGLT2i	12 (2.4%)	20 (4.0%)	0.59 (0.29–1.21)
504	semaglutide	SU	14 (2.8%)	31 (6.2%)	0.44 (0.24–0.83)
325	semaglutide	TZD	<10 (<3.1%)	20 (6.2%)	0.43 (0.20–0.95)

Hazard Ratio (HR)

0.10 0.20 0.40 0.70 2.0 3.00 5.00 8.00